These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Links between genetics and immunology: mutations and antigens. Ayyoub M Bull Acad Natl Med; 2016 Jan; 200(1):67-79. PubMed ID: 29889414 [TBL] [Abstract][Full Text] [Related]
4. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Mandal R; Chan TA Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038 [TBL] [Abstract][Full Text] [Related]
5. Targeting neoantigens to augment antitumour immunity. Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802 [TBL] [Abstract][Full Text] [Related]
6. T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors. Sioud M Scand J Immunol; 2018 Mar; 87(3):. PubMed ID: 29381830 [TBL] [Abstract][Full Text] [Related]
7. Next generation approaches for tumor vaccination. Patel A; Kaufman HL; Disis ML Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672 [TBL] [Abstract][Full Text] [Related]
8. Characterizing neoantigens for personalized cancer immunotherapy. Capietto AH; Jhunjhunwala S; Delamarre L Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383 [TBL] [Abstract][Full Text] [Related]
9. Neoantigens in cancer immunotherapy. Schumacher TN; Schreiber RD Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375 [TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. Esposito A; Criscitiello C; Curigliano G Curr Opin Oncol; 2015 Nov; 27(6):445-51. PubMed ID: 26447875 [TBL] [Abstract][Full Text] [Related]
11. Cancer Neoantigens and Applications for Immunotherapy. Desrichard A; Snyder A; Chan TA Clin Cancer Res; 2016 Feb; 22(4):807-12. PubMed ID: 26515495 [TBL] [Abstract][Full Text] [Related]
12. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade. Wilkinson RW; Leishman AJ Front Immunol; 2018; 9():1082. PubMed ID: 29910800 [TBL] [Abstract][Full Text] [Related]
13. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Chabanon RM; Pedrero M; Lefebvre C; Marabelle A; Soria JC; Postel-Vinay S Clin Cancer Res; 2016 Sep; 22(17):4309-21. PubMed ID: 27390348 [TBL] [Abstract][Full Text] [Related]
14. New emerging targets in cancer immunotherapy: the role of neoantigens. De Mattos-Arruda L; Blanco-Heredia J; Aguilar-Gurrieri C; Carrillo J; Blanco J ESMO Open; 2020 Apr; 4(Suppl 3):e000684. PubMed ID: 32269031 [TBL] [Abstract][Full Text] [Related]
16. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956 [TBL] [Abstract][Full Text] [Related]
17. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Ward JP; Gubin MM; Schreiber RD Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999 [TBL] [Abstract][Full Text] [Related]
18. The importance for immunoregulation for long-term cancer control. Fusi A; Dalgleish A Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411 [TBL] [Abstract][Full Text] [Related]
19. Unconventional T Cell Targets for Cancer Immunotherapy. Godfrey DI; Le Nours J; Andrews DM; Uldrich AP; Rossjohn J Immunity; 2018 Mar; 48(3):453-473. PubMed ID: 29562195 [TBL] [Abstract][Full Text] [Related]